×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DBVT – dbv technologies s.a. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DBVT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
08:05 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.
High
Report
DBV Technologies (NASDAQ:DBVT) had its price target raised by analysts at Citizens Jmp from $21.00 to $45.00. They now have a "market outperform" rating on the stock.
12/17
07:06 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
High
Report
DBV Technologies (NASDAQ:DBVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/17
06:04 am
dbvt
Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]
High
Report
Tesla, Netflix, Lennar, DBV Technologies, Micron, and More Stock Market Movers [Barron's]
12/17
06:02 am
dbvt
DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
High
Report
DBV Technologies (NASDAQ:DBVT) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/16
10:11 pm
dbvt
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
High
Report
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript [Seeking Alpha]
12/16
04:39 pm
dbvt
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
High
Report
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years [Yahoo! Finance]
12/16
04:05 pm
dbvt
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
High
Report
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
12/16
05:43 am
dbvt
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
DBV Technologies (NASDAQ:DBVT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
04:21 pm
dbvt
Form 8-K DBV Technologies S.A. For: Dec 16
High
Report
Form 8-K DBV Technologies S.A. For: Dec 16
12/12
01:07 pm
dbvt
Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
12/8
11:45 am
dbvt
Form SCHEDULE 13G DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SCHEDULE 13G DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
11/25
04:15 pm
dbvt
Form 4 DBV Technologies S.A. For: Nov 20 Filed by: Mohideen Pharis
Low
Report
Form 4 DBV Technologies S.A. For: Nov 20 Filed by: Mohideen Pharis
11/24
07:05 pm
dbvt
Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Boucinha Virginie
Low
Report
Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Boucinha Virginie
11/24
07:05 pm
dbvt
Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Tasse Daniel
Low
Report
Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Tasse Daniel
11/24
07:05 pm
dbvt
Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Trapp Kevin Michael
Low
Report
Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Trapp Kevin Michael
11/14
05:41 pm
dbvt
Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Venrock Healthcare Capital Partners II, L.P.
Low
Report
Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Venrock Healthcare Capital Partners II, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Bryan, Garnier & Co from a "buy" rating to a "neutral" rating.
27.9%
3/17 Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 25.8%
1/8 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy 14.8%
4/21 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 14.1%
4/14 Form 6-K DBV Technologies S.A. For: Apr 13 13.6%
4/7 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.25 price target on the stock. 10.6%
7/3 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.2%
8/7 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy 9.5%
2/26 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.7%
4/15 Monthly information regarding the total number of voting rights and total number of shares of the Company 5.8%
3/17 Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 25.8%
1/8 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy 14.8%
4/21 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 14.1%
4/14 Form 6-K DBV Technologies S.A. For: Apr 13 13.6%
4/7 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.25 price target on the stock. 10.6%
7/3 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.2%
8/7 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy 9.5%
2/26 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.7%
4/15 Monthly information regarding the total number of voting rights and total number of shares of the Company 5.8%
TOP News Decliners
3/10
DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock.
-14.2%
1/29 Form 6-K DBV Technologies S.A. For: Jan 29 -13.2%
3/12 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -11.7%
3/20 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Kepler Capital Markets from a "buy" rating to a "hold" rating. -11.6%
12/20 DBV TECHNOLOGIE/S (NASDAQ: DBVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -8.7%
2/4 Form 6-K DBV Technologies S.A. For: Feb 04 -8.6%
3/5 DBV TECHNOLOGIE/S (NASDAQ: DBVT) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $18.00 price target on the stock. -8.5%
1/9 Form 6-K DBV Technologies S.A. For: Jan 08 -8.4%
10/9 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares -8.2%
4/14 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -8.2%
1/29 Form 6-K DBV Technologies S.A. For: Jan 29 -13.2%
3/12 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -11.7%
3/20 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was downgraded by analysts at Kepler Capital Markets from a "buy" rating to a "hold" rating. -11.6%
12/20 DBV TECHNOLOGIE/S (NASDAQ: DBVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock. -8.7%
2/4 Form 6-K DBV Technologies S.A. For: Feb 04 -8.6%
3/5 DBV TECHNOLOGIE/S (NASDAQ: DBVT) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $18.00 price target on the stock. -8.5%
1/9 Form 6-K DBV Technologies S.A. For: Jan 08 -8.4%
10/9 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares -8.2%
4/14 DBV TECHNOLOGIE/S (NASDAQ: DBVT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: